[HTML][HTML] Novel Erlotinib–Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms
J Murányi, C Duró, B Gurbi, I Móra, A Varga… - International Journal of …, 2023 - mdpi.com
In a search for novel therapeutic options for head and neck squamous cell carcinomas
(HNSCCs) generally treated with limited therapeutic success, we synthesized a series of …
(HNSCCs) generally treated with limited therapeutic success, we synthesized a series of …
[HTML][HTML] Novel Erlotinib–Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms
J Murányi, C Duró, B Gurbi, I Móra… - … Journal of Molecular …, 2023 - ncbi.nlm.nih.gov
In a search for novel therapeutic options for head and neck squamous cell carcinomas
(HNSCCs) generally treated with limited therapeutic success, we synthesized a series of …
(HNSCCs) generally treated with limited therapeutic success, we synthesized a series of …
[PDF][PDF] Novel Erlotinib–Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms
J Murányi, C Duró, B Gurbi, I Móra, A Varga… - Int. J. Mol. Sci, 2023 - academia.edu
In a search for novel therapeutic options for head and neck squamous cell carcinomas
(HNSCCs) generally treated with limited therapeutic success, we synthesized a series of …
(HNSCCs) generally treated with limited therapeutic success, we synthesized a series of …
Novel Erlotinib-Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms
J Murányi, C Duró, B Gurbi, I Móra… - International …, 2023 - pubmed.ncbi.nlm.nih.gov
In a search for novel therapeutic options for head and neck squamous cell carcinomas
(HNSCCs) generally treated with limited therapeutic success, we synthesized a series of …
(HNSCCs) generally treated with limited therapeutic success, we synthesized a series of …
Novel Erlotinib-Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms.
J Murányi, C Duró, B Gurbi, I Móra, A Varga… - … Journal of Molecular …, 2023 - europepmc.org
In a search for novel therapeutic options for head and neck squamous cell carcinomas
(HNSCCs) generally treated with limited therapeutic success, we synthesized a series of …
(HNSCCs) generally treated with limited therapeutic success, we synthesized a series of …
Novel Erlotinib–Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms
J Murányi, C Duró, B Gurbi, I Móra… - International …, 2023 - search.proquest.com
In a search for novel therapeutic options for head and neck squamous cell carcinomas
(HNSCCs) generally treated with limited therapeutic success, we synthesized a series of …
(HNSCCs) generally treated with limited therapeutic success, we synthesized a series of …
Novel Erlotinib–Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms.
J Murányi, C Duró, B Gurbi, I Móra… - International …, 2023 - search.ebscohost.com
In a search for novel therapeutic options for head and neck squamous cell carcinomas
(HNSCCs) generally treated with limited therapeutic success, we synthesized a series of …
(HNSCCs) generally treated with limited therapeutic success, we synthesized a series of …
Novel Erlotinib–Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms
J Murányi, C Duró, B Gurbi, I Móra, A Varga, K Németh… - IJMS, 2023 - agris.fao.org
In a search for novel therapeutic options for head and neck squamous cell carcinomas
(HNSCCs) generally treated with limited therapeutic success, we synthesized a series of …
(HNSCCs) generally treated with limited therapeutic success, we synthesized a series of …